All News

CDC.jpg (keep)

CDC: Impact of Underlying Health Conditions Among COVID-19 Patients

d Jack Cush, MD

The March 31 release of the Morbidity and Mortality Weekly Report (MMWR) reviews the impact of several key comorbidities, most commonly diabetes mellitus, chronic lung disease, and cardiovascular disease, as cofactors leading to worse outcomes with COVID-19 infections.  Below are e

Read Article
TeleRheumatology_0.jpg

TeleRheumatology - a TED Talk by Alvin Wells, MD

d Jack Cush, MD

RheumNow Live 2020 featured a series of shorter STEP (TED-like) talks. This one features Dr. Alvin Wells discussing the opportunities and new paradigms encumbent with telemedicine in rheumatology.

Read Article
A PODCAST - Rheum Patient PSA on how to manage your arthritis, meds, biologics, misinformation, safety and STRESS in the time of COVID-19 (a 44:01 minute compilation of 5 PSA podcasts) https://t.co/ENrORXRDqz

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow PSA 1 -- How to Manage your Arthritis Medications (in the time of COVID) - View the video here: https://t.co/egUTpxfx96 or listen to the podcast on iTunes or here>> https://t.co/8wV4V2pYY5

Links:

Dr. John Cush RheumNow ( View Tweet)

Listen to Dr. Jack Cush from @RheumNow interview @philipcrobinson about The COVID-19 Global Rheumatology Alliance https://t.co/aZLsZnAoP3

Links:

The COVID-19 Global Rheumatology Alliance rheum_covid ( View Tweet)

Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis - https://t.co/kDbNqo2Pii

Links:

Drugs.com Drugscom ( View Tweet)

Be careful, QT prolongation is a known effect of chloroquine and hydroxychloroquine. Could be worsened when used with azithromycin. Death and problems reported from France. https://t.co/sKekD9A8Yt

Links:

Dr. Janet Woodcock DrWoodcockFDA ( View Tweet)

Survival in lung cancer patients with RA is less than that of those without RA (worse w/ RA-ILD). Study of a cohort 154 lung CA pts (18 with RA,136 without RA) compared propensity matched 18 RA vs 36 without RA and Lung CA. https://t.co/zint9QICE1

Links:

Dr. John Cush RheumNow ( View Tweet)

NEJM article on renin-angiotensin-aldosterone inhibitors may increase ACE2 & Covid-19 binding but, "Insufficient data available to determine whether observations translate to humans...no studies have evaluated ...RAAS inhib in Covid-19" https://t.co/x39oCgRTp1

Links:

Dr. John Cush RheumNow ( View Tweet)

#Skin Manifestations in #COVID19. A very recent article appeared in the @TheJEADV regarding the #dermatological findings in #Covid_19 infection in #Italy. The authors report that (20.4%) developed cutaneous manifestations. More info ... 👇 #dermatology https://t.co/r1CVcbIUUJ
Dr. Ramon Grimalt DrRamonGrimalt ( View Tweet)
If you want more proof we waste medical school years teaching low value topics (krebs cycle) while failing to teach high value topics (evidence appraisal) then just note how many docs self prescribed hydroxychlorquine and horded it.

Vinay Prasad VPrasadMDMPH ( View Tweet)

Our letter (& color fig!) HCQ in COVID @AnnalsofIM Great experience writing with @rheum_covid folks, including @rheum_cat @alhkim @jeffsparks @Larhumato @AliDuarteMD @SituationRheum @pekor002 @SattuiSEMD @emilysirotich @mugartegil @drkatiewebb @Drbeckyg https://t.co/KzeMXAT6rd https://t.co/dFVW7LyXfR

Links:

Mike Putman EBRheum ( View Tweet)
Should Rheum & Derm pts stop biological during #Covid_19? Likely not as a flare may put pts at risk of seeking medical attention or adding steroids. The #outbreak won’t be over for awhile. Ontario Rheum Assoc says take meds unless fever/SOB. J Article review @RheumNow @RheumInfo https://t.co/KDFAq482jt
Janet Pope Janetbirdope ( View Tweet)
This brief correspondence discusses the risks of uncontrolled RA and lupus resulting in increased risk of infection. (via @emilysirotich) Argues for continuing current treatments for our pts w/ inflammatory conditions (for now) https://t.co/o32cxeLsBL https://t.co/CoNeM8G6fq

Links:

Dr. Paul Sufka psufka ( View Tweet)
HCQ in non-severe hospitalized COVID19, new single center RCT of 62pts Sx resolved ~1d sooner, a few more cleared CT findings Not peer rvwd, underpowered, unclear blinding/allocation, soft/non-validated outcomes, poorly reported Need. GOOD. RCTs. PDF: https://t.co/Mbrq7bFHk0 https://t.co/LcD2wbgyZm

Links:

Mike Putman EBRheum ( View Tweet)
Listen to Dr. Alvin Wells "TED" like talk from RheumNow Live on 3/14/20 on why rheumatologists should be doing TeleRheumatology! Listen on iTunes or here>> https://t.co/279mKHnO3A

Links:

Dr. John Cush RheumNow ( View Tweet)

Inzomelid, a selective, orall small molecule inhibitor of the NLRP3 inflammasome, has been tested in a phase I trial of CAPS (Cryopyrin-Associated Periodic Syndrome) https://t.co/8gO63xO9bC

Links:

Dr. John Cush RheumNow ( View Tweet)

Which DMARD goes best w/ a biologic? Metanalysis of 41 studies shows w/ TNFi, MTX is superior to other DMARDs; with RTX adding LEF is superior to MTX and with ABA the addition of MTX and non-MTX csDMARDs were equally effective. https://t.co/ukBNxR9c1u

Links:

Dr. John Cush RheumNow ( View Tweet)

Corona infections are trending down in China, with no new cases reported in Hubei province, for the sixth consecutive day on Sunday. https://t.co/aY0SHzxyoJ

Links:

Dr. John Cush RheumNow ( View Tweet)

The FDA has approved the investigational use of COVID-19 Convalescent Plasma - allowing clinicians to use as single-patient emergency Investigational New Drug Applications (INDs) - Must apply w/ form 3926 https://t.co/2oYWEYiB4f

Links:

Dr. John Cush RheumNow ( View Tweet)

×